Radiogenomics and Its Role in Lymphoma

Curr Hematol Malig Rep. 2020 Jun;15(3):211-224. doi: 10.1007/s11899-020-00577-2.

Abstract

Purpose of review: Imaging features of lymphoma vary regionally. Awareness of site-specific key imaging characteristics of lymphoma can aid in rapid staging and assist in prompt treatment. FDG PET/CT and conventional MRI are readily available diagnostic modalities with excellent sensitivity and good specificity. Diagnostic specificity can be enhanced using emerging PET radiotracers, e.g., FLT and FET.

Recent findings: Emerging research has shown higher dimensional analysis (radiomics and radiogenomics) of imaging data can yield information of the underlying genetic aberrations in lymphoma, which can aid in assessing real-time evolution of tumor. CT, PET/CT, MRI, and ultrasound accentuate the intrinsic qualities of lymphoma (e.g., FDG PET/CT for increased metabolic activity, FLT PET/CT for increased proliferation index, and DWI for increased cellularity) and play an essential role in its diagnosis and examination. Advanced radiogenomic analyses use radiomic parameters to deduce genetic variations of lymphoma, providing noninvasive, repeatable, and real-time surveillance of its genetic progression.

Keywords: Hodgkin’s lymphoma; Imaging biomarkers; Lymphoma; Non-Hodgkin’s lymphoma; Radiogenomics; Radiomics.

Publication types

  • Research Support, N.I.H., Extramural
  • Review

MeSH terms

  • Biomarkers, Tumor / genetics*
  • Diffusion Magnetic Resonance Imaging*
  • Fluorodeoxyglucose F18 / administration & dosage
  • Humans
  • Lymphoma / diagnostic imaging*
  • Lymphoma / genetics
  • Lymphoma / therapy
  • Molecular Imaging*
  • Positron Emission Tomography Computed Tomography*
  • Predictive Value of Tests
  • Prognosis
  • Radiopharmaceuticals / administration & dosage
  • Reproducibility of Results

Substances

  • Biomarkers, Tumor
  • Radiopharmaceuticals
  • Fluorodeoxyglucose F18